TYSABRI (also known as Natalizumab)
Tysabri is an antibody that binds to a cell adhesion molecule called integrin and thereby reduces the ability of inflammatory cells to pass through the lining of the intestines and blood-brain barrier. Of note, due to the increased risk of a viral infection called progressive multifocal leukoencephalopathy (PML), Tysabri is available only through a special restricted distribution program.
- Relapsing multiple sclerosis
- Active, severe Crohn’s Disease
Patients with a history of PML should not be started on Tysabri.
Tysabri is typically administered as an infusion over sixty minutes and repeated every 4 weeks.